Given our demonstration that AF6 affects the regulation of both cell death and pro-inflammatory signaling pathways, we assessed these effects in other mouse models of liver diseases, including those for acute liver injury, liver fibrosis and diabetes. Here, AFDN is linked to diabetes mellitus.